News from novartis pharmaceuticals corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

07:30 ET Novartis premieres powerful new docuseries at Tribeca Festival to shine a light on debilitating skin disease

Produced in partnership with advocate, journalist and filmmaker Jasmine IVANNA Espy, "The Beacons: Illuminating HS Stories" offers an intimate look...

Jun 02, 2023, 08:05 ET Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with...

Apr 20, 2023, 01:17 ET Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis...

Mar 27, 2023, 01:20 ET Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer

Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1...

Dec 13, 2022, 10:00 ET Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5

Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult ...

Dec 08, 2022, 01:15 ET Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH

Phase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for...

Dec 06, 2022, 13:45 ET Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy

RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral...

Jun 22, 2022, 07:30 ET Novartis expands Beacon of Hope through alliances with Historically Black Medical Schools to address systemic health disparities

Novartis commits additional $17.7 million to create Clinical Trial Centers of Excellence at Howard University College of Medicine, Meharry Medical...

Apr 06, 2022, 08:00 ET FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a...

Mar 23, 2022, 20:27 ET Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer

FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive...

Dec 22, 2021, 18:53 ET Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis

Novartis, a leader in rheumatology and immuno-dermatology, today announced the US Food and Drug Administration (FDA) has approved Cosentyx®...

Dec 22, 2021, 16:23 ET La FDA aprueba Leqvio® (inclisiran) de Novartis, el primer ARNip de su clase para reducir el colesterol y mantenerlo bajo con dos dosis al año

- Con dos dosis de mantenimiento al año, Leqvio es el primer y único tratamiento de ARN de interferencia pequeño (ARNip) aprobado por la FDA para la...

Dec 22, 2021, 16:23 ET FDA 批准Novartis 的 Leqvio® (inclisiran)，这是一种可降胆固醇且每年两剂即可维持效果的首创 siRNA

Novartis 今天宣布，美国食品药品监督管理局 (FDA) 批准 Leqvio® (inclisiran)，这是第一款也是唯一一款用于降低低密度脂蛋白胆固醇（也称为坏胆固醇或 LDL-C）的小干扰 RNA (siRNA) 疗法，在给予初始剂量和第三个月的一剂给药后，可每年两次给药。...

Dec 22, 2021, 16:23 ET FDA核准Novartis Leqvio® (inclisiran)，這是一種可降膽固醇且每年兩劑即可維持效果的首創 siRNA

Novartis 今日宣布美國食品藥物管理局（FDA）核准 Leqvio® (inclisiran)，這是第一個也是唯一一個小型干擾 RNA（siRNA）療法，用於降低低密度脂蛋白膽固醇（也稱為壞膽固醇或 LDL-C），在初始劑量和三個月後再給予一劑之後，每年僅需兩劑。 Novartis 總裁...

Dec 22, 2021, 16:22 ET FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year

Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio® (inclisiran), the first and only small interfering RNA (siRNA) ...

Dec 10, 2021, 08:02 ET Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Novartis today announced new Piqray® (alpelisib) data indicating benefit across a broad range of patient and disease characteristics as seen in...

Dec 08, 2021, 09:32 ET New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

Novartis today announced new Kisqali® (ribociclib) data demonstrating a consistent overall survival (OS) benefit with Kisqali plus endocrine therapy...

Nov 04, 2021, 13:57 ET Novartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G)

Novartis today announced that a Phase II study of investigational iptacopan (LNP023) – a first-in-class, oral, selective factor B inhibitor – in...

Sep 16, 2021, 18:10 ET Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021

Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an...

Aug 31, 2021, 08:24 ET Novartis launches "Meet The PROS" to raise awareness and support education for PIK3CA-Related Overgrowth Spectrum (PROS)

Novartis today announced the launch of "Meet The PROS," an initiative to raise awareness and offer new educational resources for PIK3CA-Related...

Jun 04, 2021, 09:08 ET Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor...

Jun 03, 2021, 17:06 ET Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera® (INN: lutetium (177Lu)...

Jun 03, 2021, 12:24 ET Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study

Novartis today announced that results of the Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of...

Jun 02, 2021, 09:10 ET Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients

Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in postmenopausal...

Jun 01, 2021, 16:42 ET Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis

Novartis, a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx®...